ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0039

Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?

Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2021

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), iga, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites and has an important function in intestinal homeostasis. Therefore, it is worthwhile to study this isotype in more detail in the context of RA. Humans have two IgA subclasses, IgA1 and IgA2, which are not evenly distributed. IgA1 is dominant in serum, whereas IgA1 and IgA2 are more balanced at mucosal surfaces (2). Besides these differences in location, IgA2 has also been ascribed pro-inflammatory properties (3). As IgA subclasses might provide insights into mucosal involvement and potential pro-inflammatory mechanisms in RA, we measured total and autoantibody specific IgA subclasses in sera of rheumatoid arthritis patients.

Methods: RA patients from two cohorts, the IMPROVED and the EAC, were selected based on previous autoantibody measurements. Samples were collected at baseline in the IMPROVED study and at the 1-year visit in the EAC. All patients fulfilled the 1987 (EAC) or 2010 (IMPROVED) ACR criteria for RA. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and total IgA subclasses were measured in these sera using in-house ELISA’s, and compared to healthy donors. The association of IgA subclass levels with CRP, disease activity score (DAS) and smoking was investigated using Spearman’s rank correlation and Mann–Whitney U tests.

Results: Both total IgA1 and IgA2 were increased in seropositive RA, but not in seronegative RA patients in the IMPROVED (Figure 1). In seropositive RA, both IgA subclasses were raised to the same extent. RF and ACPA IgA1 and IgA2 were also detected in seropositive RA patients (Figure 2), but measurements of ACPA IgA2 levels proved challenging due to interference of RF IgA and are therefore not depicted. Although IgA2 has been postulated to be more proinflammatory, no relevant associations were found between total, RF and ACPA IgA subclass levels and CRP (Figure 3A, IMPROVED only) or DAS. In smoking seropositive RA patients, a selective minor increase in total IgA2, RF IgA1 and RF IgA2 was seen in both cohorts (Figure 3B, IMPROVED only), although all were non-significant in the EAC.

Conclusion: Seropositive RA patients have equally raised IgA1 and IgA2 levels and can also harbor RF and ACPA IgA subclasses. No indications of a mucosal source, such as a predominance of total IgA2, were found, although smokers might have slightly increased total IgA2. However, these results do consolidate the concept that seropositive versus seronegative RA have different pathophysiological traits, with seropositive patients perhaps displaying more aspecific B cell hyperreactivity.

References:
(1) Holers, Nat rev rheumatol 2018
(2) Woof, Mucosal immunol 2011
(3) Steffen, Nat commun 2020

Figure 1: total IgA1 and IgA2 levels in seropositive and seronegative RA patients

Figure 2: RF IgA1 & IgA2 levels and anti-CCP2 IgA1 levels in RA patients

Figure 3: A) Association of total and autoantibody IgA subclasses with CRP in IMRPOVED B) Association of total and autoantibody IgA subclasses with smoking in IMPROVED


Disclosures: V. Derksen, None; C. Allaart, Dutch College of Health Insurances, 5, Schering-Plough BV, 5, Centocor Inc., 5, Eli Lilly, 5; A. van der Helm-van Mil, None; T. Huizinga, None; R. Toes, None; D. van der Woude, None.

To cite this abstract in AMA style:

Derksen V, Allaart C, van der Helm-van Mil A, Huizinga T, Toes R, van der Woude D. Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/elevated-iga-subclass-levels-in-rheumatoid-arthritis-patients-indications-of-a-mucosal-origin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-iga-subclass-levels-in-rheumatoid-arthritis-patients-indications-of-a-mucosal-origin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology